- Home
- LOGC vs PBYI Comparison
LOGC vs PBYI Comparison
Compare LOGC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGC
- PBYI
- Stock Information
- Founded
- LOGC 2010
- PBYI 2010
- Country
- LOGC United States
- PBYI United States
- Employees
- LOGC N/A
- PBYI N/A
- Industry
- LOGC Catalog/Specialty Distribution
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- LOGC Consumer Discretionary
- PBYI Health Care
- Exchange
- LOGC Nasdaq
- PBYI Nasdaq
- Market Cap
- LOGC 185.5M
- PBYI 152.4M
- IPO Year
- LOGC 2020
- PBYI N/A
- Fundamental
- Price
- LOGC $8.20
- PBYI $3.28
- Analyst Decision
- LOGC
- PBYI Strong Buy
- Analyst Count
- LOGC 0
- PBYI 1
- Target Price
- LOGC N/A
- PBYI $7.00
- AVG Volume (30 Days)
- LOGC 265.6K
- PBYI 375.3K
- Earning Date
- LOGC 05-09-2025
- PBYI 05-08-2025
- Dividend Yield
- LOGC N/A
- PBYI N/A
- EPS Growth
- LOGC N/A
- PBYI 143.51
- EPS
- LOGC N/A
- PBYI 0.77
- Revenue
- LOGC $7,000,000.00
- PBYI $232,709,000.00
- Revenue This Year
- LOGC $433.37
- PBYI N/A
- Revenue Next Year
- LOGC N/A
- PBYI N/A
- P/E Ratio
- LOGC N/A
- PBYI $4.25
- Revenue Growth
- LOGC N/A
- PBYI 2.68
- 52 Week Low
- LOGC $4.92
- PBYI $2.23
- 52 Week High
- LOGC $9.34
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- LOGC 65.72
- PBYI 52.36
- Support Level
- LOGC $7.64
- PBYI $3.14
- Resistance Level
- LOGC $8.22
- PBYI $3.45
- Average True Range (ATR)
- LOGC 0.35
- PBYI 0.19
- MACD
- LOGC 0.05
- PBYI 0.01
- Stochastic Oscillator
- LOGC 98.25
- PBYI 51.19
About LOGC ContextLogic Inc.
ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives majority of its revenue from Europe and also has a presence in North America; South America, and other countries.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.